PolyNovo
PNV.ASXHealth Care
PolyNovo develops and commercialises innovative medical devices using its NovoSorb technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.
Market Data
$1.200
-0.0%$842.8M
85.3x
$0.014
0.00%
-0.1%
Latest Earnings
Appendix 4D & H1 FY26 Financial Statements
20 February 2026
PolyNovo delivered strong commercial growth with group sales up 26.0% to A$68.2m in H1 FY26, driven by 195.2% growth in NovoSorb MTX sales and expansion across all key markets. Net profit essentially flat at A$0.0m (vs A$3.3m prior year) due to reduced manufacturing output for PMA submission preparation and R&D laboratory fire impact, though EBITDA adjusted for significant items increased 82.0%. The company completed construction of its additional manufacturing facility and remains well-positioned for continued growth with multiple catalysts ahead. Key points: Strong commercial sales growth of 26.0% to A$68.2m with expansion across all key markets; NovoSorb MTX delivered exceptional 195.2% growth reaching A$6.2m in sales; U.S. market performance remained robust with 25.3% growth to A$51.7m
Recent Announcements
Ceasing to be a substantial holder
UBS Group AG ceased to be a substantial holder.
Becoming a substantial holder
UBS Group AG became a substantial holder (5.42%).
Webcast Recording - 1H26 Financial Results
PolyNovo (ASX: PNV) has made available a webcast recording of its H1 FY26 financial results presentation, including updates from the Chair and CEO, financial results, and Q&A session for shareholders unable to attend the live event.
Appendix 4D & H1 FY26 Financial Statements
PolyNovo delivered strong commercial growth with group sales up 26.0% to A$68.2m in H1 FY26, driven by 195.2% growth in NovoSorb MTX sales and expansion across all key markets. Net profit essentially flat at A$0.0m (vs A$3.3m prior year) due to reduced manufacturing output for PMA submission preparation and R&D laboratory fire impact, though EBITDA adjusted for significant items increased 82.0%. The company completed construction of its additional manufacturing facility and remains well-positioned for continued growth with multiple catalysts ahead. Key points: Strong commercial sales growth of 26.0% to A$68.2m with expansion across all key markets; NovoSorb MTX delivered exceptional 195.2% growth reaching A$6.2m in sales; U.S. market performance remained robust with 25.3% growth to A$51.7m
Earnings Release - 20 February 2026
Upcoming earnings release expected 20 February 2026 (from Yahoo Finance (confirmed))
Appendix 4E and FY25 Financial Statements
PolyNovo delivered exceptional FY25 results with group sales reaching A$118.6m (+28.9% YoY) and net profit surging 151.2% to A$13.2m, driven by strong NovoSorb MTX commercial traction following its U.S. launch and geographic expansion to 46 countries. The company is investing heavily in growth infrastructure with a new manufacturing facility on track for completion by December 2025, while maintaining a strong cash position of A$33.5m after debt repayment and capex. Key points: Commercial sales growth of 28.9% to A$118.6m with record monthly sales in June (A$12.8m), March (A$11.9m), and November (A$10.1m); Net profit surged 151.2% to A$13.2m and EBITDA increased 209.3% to A$11.2m demonstrating significant operating leverage; NovoSorb MTX U.S. launch achieved A$6.7m sales in FY25 with FDA clearance expanded to 6mm and new indications (tunnelled/undermined wounds) in March 2025
Get real-time alerts for PNV
Receive AI-powered earnings summaries and instant notifications when PolyNovo releases results.
Register Free